BRIEF-Dechra Pharmaceuticals full year revenue up 21.7 pct

September 5, 2016 6:12 AM

50 0

* Fy revenue growth in our existing eu pharmaceuticals segment was 5.7pct (at cer)

* Product development pipeline continues to deliver results: recently launched products osphos  and zycortal  gaining good market penetration.

Also read: IMF Sees U.S. Potential Growth at Half the Pace of White House Estimates

Read more

To category page

Loading...